Encorafenib plus binimetinib prolongs OS for advanced BRAF-mutated melanoma

Source: Healio, June 2018

Combination therapy with encorafenib plus binimetinib significantly improved OS compared with vemurafenib or encorafenib alone for patients with advanced BRAF-mutated melanoma, according to phase 3 results from the COLUMBUS trial presented at ASCO Annual Meeting.
Encorafenib (LGX818, Array BioPharma) plus binimetinib (MEK162, Array BioPharma) — a BRAF/MEK inhibitor combination — conferred a best-in-class median PFS of 14.9 months and median OS of 33.6 months. In comparison, vemurafenib (Zelboraf, Genentech) monotherapy conferred a median PFS of 7.3 months and median OS of 16.9 months, and encorafenib monotherapy conferred a median PFS of 9.6 months and median OS of 23.5 months.
“Encorafenib plus binimetinib combination therapy provides a new efficacy benchmark for targeted therapy and it is a promising treatment option for patients with BRAFV600-mutant melanoma,” Reinhard Dummer, MD, from the department of dermatology at University of Zurich Hospital in Zurich, Switzerland, said during his presentation.
read the original full article